Article Details

USFDA accepts AstraZeneca's BLA for nirsevimab to prevent RSV lower respiratory tract disease

Retrieved on: 2023-01-06 09:30:34

Tags for this article:

Click the tags to see associated articles and topics

USFDA accepts AstraZeneca's BLA for nirsevimab to prevent RSV lower respiratory tract disease. View article details on hiswai:

Excerpt

The United States Food and Drug Administration (USFDA) has accepted AstraZeneca's Biologics Licence Application (BLA) for nirsevimab for review to ...

Article found on: www.expresspharma.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up